Atherosclerotic plaque rupture: Emerging insights and opportunities

American Journal of Cardiology

Volumn 84, Issue 1 A, 1999, Pages 15-20

  Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; CD40 ANTIGEN; CYTOKINE; LIGAND; MATRIX METALLOPROTEINASE; ROSIGLITAZONE; TROGLITAZONE;

ATHEROSCLEROTIC PLAQUE; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; EXTRACELLULAR MATRIX; HEART INFARCTION; HUMAN; INFLAMMATORY CELL; PALLIATIVE THERAPY; PRIORITY JOURNAL; RUPTURE; THROMBOSIS; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0033536207     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00352-5     Document Type: Conference Paper

References (23)

1. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
2. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., Hjemdahl-Monsen C.E., Leavy J., Weiss M., Borrico S., Gorlin R., Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 12:1988;56-62.
3. Little W.C., Downes T.R., Applegate R.J. The underlying coronary lesion in myocardial infarction implications for coronary angiography . Clin Cardiol. 14:1991;868-874.
4. Nobuyoshi M., Tanaka M., Nosaka H., Kimura T., Yokoi H., Hamasaki N., Kim K., Shindo T., Kimura K. Progression of coronary atherosclerosis is coronary spasm related to progression? J Am Coll Cardiol. 18:1991;904-910.
5. Giroud D., Li J.M., Urban P., Meier B., Rutishauser W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 69:1992;729-732.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
7. Amento E.P., Ehsani N., Palmer H., Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 11:1991;1223-1230.
8. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
9. Shah P.K., Falk E., Badimon J.J., Fernandez-Ortiz A., Mailhac A., Villareal-Levy G., Fallon J.T., Regnstrom J., Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques potential role of matrix-degrading metalloproteinases and implications for plaque rupture . Circulation. 92:1995;1565-1569.
10. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma a potential mechanism of lesion stabilization . Circulation. 97:1998;2433-2444.
11. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
12. Mach F., Schönbeck U., Libby P. CD40 signaling in vascular cells a key role in atherosclerosis? Atherosclerosis. 137:(suppl):1998;S89-S95.
13. Mach F., Schönbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 394:1998;200-203.
14. Schoonjans K., Martin G., Staels B., Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 8:1997;159-166.
15. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
16. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
17. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPARγ differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro . Am J Pathol. 153:1998;17-23.
18. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 95:1998;7614-7619.
19. Tontonoz P., Nagy L., Alvarez J.G.A., Thomazy V.A., Evans R.M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
20. Nagy L., Tontonoz P., Alvarez J.G.A., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell. 93:1998;229-240.
21. Marx N., Bourcier T., Sukhova G.K., Libby P., Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression PPARγ as a potential mediator in vascular disease . Arterioscler Thromb Vasc Biol. 19:1999;546-551.
22. Marx N., Schönbeck U., Lazar M.A., Libby P., Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 83:1998;1097-1103.
23. Law R., Meehan W.P., Xi X.-P., Graf K., Wuthrich D.A., Coats W., Faxon D., Hsueh W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98:1996;1897-1905.